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Abstract
Over a decade has passed since the first human papillomavirus (HPV) vaccine
was introduced. These vaccines have received unequivocal backing from the
scientific and medical communities, yet continue to be debated in the media and
within the public. The current review is an updated examination that the authors
made 5 years ago on some of the key sociocultural and behavioral issues
associated with HPV vaccine uptake and acceptability, given the changing
vaccine policies and beliefs worldwide. We explore current worldwide HPV
vaccination rates, outline HPV vaccine policies, and revisit critical issues
associated with HPV vaccine uptake including: risk compensation, perceptions of
vaccine safety and efficacy, age of vaccination, and healthcare provider (HCP)
recommendation and communication. While public scrutiny of the vaccine has
not subsided, empirical evidence supporting its safety and efficacy beyond
preventing cervical cancer has amassed. There are conclusive findings showing
no link that vaccinated individuals engage in riskier sexual behaviors as a result
of being immunized (risk compensation) both at the individual and at the policy
level. Finally, HCP recommendation continues to be a central factor in vaccine
uptake. Studies have illuminated how HCP practices and communication enhance
uptake and alleviate misperceptions about vaccination. Strategies such as
bundling vaccinations, allowing nurses to vaccinate via “standing orders,” and
diversifying vaccination settings (e.g., pharmacies) may be effective steps to
increase rates. The successes of vaccination outweigh the controversy, but as the
incidence of HPV-related cancers rises, it is imperative that future research on
HPV vaccine acceptability continues to identify effective and targeted strategies
to inform HPV vaccination programs and improve HPV coverage rates
worldwide.
Key Points
We examine key sociocultural and behavioral issues associated with HPV vaccine uptake
and acceptability, including risk compensation, perceptions of vaccine safety and
efficacy, age of vaccination, and healthcare provider (HCP) recommendation and
communication.
There are conclusive findings showing no link that vaccinated individuals engage in
riskier sexual behaviors as a result of being immunized (risk compensation).
An HCP recommendation continues to be a central factor in vaccine uptake. Strategies
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such as bundling vaccinations, allowing nurses to vaccinate via “standing orders,” and
diversifying vaccination settings (e.g., pharmacies) may be effective steps to increase
rates.
The successes of HPV vaccination outweigh the controversy.
Future research on HPV vaccine acceptability continues to identify effective and targeted
strategies to inform HPV vaccination programs and improve HPV coverage rates
worldwide.
1. Background
Five years ago, we published a paper examining myths and misinformation
surrounding HPV vaccine [1]. Since that time the HPV vaccine context has changed
in several respects: (i) A number of countries are now recommending, funding, and
vaccinating both males and females [2, 3]. (ii) A 9-valent vaccine (9vHPV) has
been introduced [4]. (iii) An increasing number of countries have implemented
publically funded national HPV vaccination programs for girls and boys [3, 5, 6].
(iv) There are more and more reports demonstrating long-term vaccine
effectiveness [7, 8, 9, 10], including a recent study showing that HPV vaccine
prevents invasive HPV-related cancers beyond cervical cancer [11]. (v) There is an
accumulated body of evidence that HPV vaccines are very safe [12, 13, 14].
Despite continued empirical evidence of the vaccines’ safety and effectiveness, and
the broad backing of HPV vaccination from the medical and scientific communities,
many countries continue to report that HPV vaccine uptake rates are low or have
dropped steeply, often related to incorrect attributions of harm [15, 16, 17, 18].
The intent of this paper, as with our 2013 article [1], is not to provide a systematic
review of behavioral science research about HPV vaccination. Rather, it is to
provide an updated, targeted commentary that addresses a specific set of topics
concerning HPV vaccination that we consider timely and important in the evolving
landscape. We revisit and update the issues that were first addressed in our previous
publication concerning myths and misinformation about HPV vaccination and
discuss whether these issues “can be put to rest” or remain pertinent. In addition,
we present and discuss new issues that have surfaced over the last 5 years and
discuss challenges that may arise in the years to come.
Over a decade has passed since the first human papillomavirus (HPV) vaccine,
Gardasil , was licensed in Gabon in 2006. Currently, three HPV vaccines are
available: The bivalent vaccine (2vHPV) Cervarix  (GSK, Rixensart, Belgium), the
quadrivalent (4vHPV) vaccine, Gardasil  (Merck, Kenilworth, NJ, USA), and the
®
®
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nonavalent (9vHPV) vaccine Gardasil  9 (Merck). All three vaccines protect
against the two oncogenic HPV genotypes, 16 and 18, which are high-risk types,
and are responsible for 70% of all cervical cancers and are also associated with
other cancer sites e.g., penis, vagina, vulva, anus, oral cavity and oropharynx [7,
19]. 4vHPV and 9vHPV also protect against genotypes 6 and 11, which are
responsible for 85% of genital warts [20]. 9vHPV offers protection against five
additional high-risk HPV genotypes, 31, 33, 45, 52, and 58, which means that this
vaccine can prevent 80–90% of cervical cancers. With the development of this
vaccine, “virtual elimination of this disease [cervical cancer] in vaccinated women
is likely” [21], particularly in the context of continued cervical cancer-screening
programs and wide population vaccine coverage.
2. Current Worldwide Estimates of HPV Vaccine
Uptake Rates
To date, 4vHPV or 9vHPV has been approved in 129 countries and over 270
million doses of the vaccine have been distributed worldwide [5]. As of June 2017,
there were an estimated 90 national publicly funded HPV vaccination programs and
38 pilot programs, with many of these implemented in low- and middle-income
countries [22] (see Fig. 1). The most extensive estimates report a worldwide
coverage of 6.1% (95% CI 4.9–7.1) among females aged 10–20 years, with a 33.6%
coverage (95% CI 25.9–41.7) in more developed regions and a mere 2.7% coverage
(95% CI 1.8–3.6) in less developed regions [6].
Fig. 1
Global progress in HPV vaccine introduction (June, 2017).
(From Cervical Cancer Action. Global maps: global progress in HPV vaccination.
2017. Available at: http://www.cervicalcanceraction.org/comments/comments3.php.
Accessed 24 Aug 2017)
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HPV vaccine uptake rates have varied widely—not only from country to country,
but also within the same country or jurisdictions (i.e., state/provincial, regional,
local, and territorial differences) [6] due to differing programs, access to services,
as well as the attitudes and beliefs towards HPV vaccination of the citizens, policy
makers, and/or community leaders in the different areas/regions [2, 23, 24, 25].
Australia has been a leader with respect to HPV vaccination, being the first country
to introduce an HPV vaccination free of charge for girls (in 2007), followed by
boys (in 2013) in a national HPV vaccination program. The program has been
deemed highly successful, leading to a decline of up to 92% in cervical HPV types
among women aged 18–35 years, a 54% reduction in the incidence of high-grade
cervical abnormalities in girls under 18 years of age, and a 90% reduction in genital
warts in heterosexual men and women under 21 years of age [26, 27, 28, 29].
Virtually every school in Australia has chosen to participate in the program, and
rates of 81.5% for one dose and 71.4% for three-dose completion have been
reported [30],
In the USA, the HPV vaccine is funded nationally by the Vaccines for Children
program and by private insurance, and is required to be covered by the Affordable
Care Act. In 2016, in the USA, 43.4% of adolescents (49.5% of females; 37.5% of
males) were up to date  with the HPV vaccination series recommendations, which
was a small increase in coverage from the year prior (2.8% increase for females;
4.6% increase for males) [31]. Importantly, substantial variation has been reported
by state, with HPV vaccine series completion rates as high as 73.0% for females
and 68.7% among males in Rhode Island and as low as 33.9% for females and
19.9% among males in Wyoming [31].
Canada’s vaccination program differs from its US neighbor in two major ways:
First, the HPV vaccine is predominantly administered through publicly funded
school-based provincial programs across the country with minor variations in the
vaccination schedule and age/school-grade of the program across the provinces. In
Canada, all ten provinces and three territories have publicly funded school-based
HPV vaccination programs for females in place, and all provinces and territories
have begun or are in the process of implementing publically funded school-based
HPV vaccination programs for boys [32]. Unlike the USA, Canada does not have a
national vaccination surveillance program, and each province differs in their data
collection procedures, vaccination target age, years reported, and linking registries.
For these reasons, a fully accurate national Canadian HPV vaccine uptake rate is
not provided [33, 34]. Perhaps the closet national estimate for Canada comes from a
1
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recent systematic review and meta-analysis, which, using a pooled random effects
model, found that the HPV vaccination uptake rate in Canada was 55.92% [35].
As is the case in the USA, Canada’s HPV vaccine rates vary by province and by
jurisdiction [36], with HPV vaccine completion rates for females as high as 89.2%
in Newfoundland and Labrador (three doses, females) and as low as 39.3% (three
doses, females) in the Northwest Territories [36]. A report from Public Health
Ontario examining vaccination records for 13-year-old females reported a
complete-for-age HPV coverage rate of 61% for the 2015–2016 school year, far
from the 90% HPV vaccine coverage goal wanted by the Canadian Immunization
Committee [37]. The available data for HPV vaccine uptake rates for Canadian
males is limited due to the recent initiation of the programs, but rates as high as
66.0–81.4% (three doses, males) have been reported in the provinces of Prince
Edward Island (PEI) and Alberta [38].
Across Europe, all 28 European Union (EU) countries have implemented HPV
vaccination [39], where vaccine uptake rates have been reported as low as 10%
(three doses, females) in Poland [25, 40], 43% in Luxembourg (three doses,
females) [41] 82% in Denmark (three doses, females), 27–83% among the
administrative regions of Italy (three doses, females) and as high as 86% (three
doses, females) in the UK [29, 42] and 90% (three doses, females) in Flanders,
Belgium [43, 44]. Disparities across central and South America have also been
reported e.g., Haiti (31%), Brazil (85%), and Bolivia (77%) [25]. This has been
largely due to variations in funding (e.g., whether or not funding was supported by
the Pan American Health Organization (PAHO) Revolving Fund). Uptake rates in
Asian countries are not as easily accessible to report; however, the introduction of
HPV vaccination has begun in some Asian cities, e.g., an uptake rate of 87% for
two doses in females in Ayutthaya province in Thailand, [45] or is underway, e.g.,
China was set to introduce HPV vaccination in community health centers across 17
provinces starting in October 2017 [46]. In Israel, universal school-based
vaccination programs for middle-school girls were introduced in 2013, and have
achieved coverage rates of ~ 60%. Uptake in Israel has differed across the country,
with similar barriers reported elsewhere, e.g. religious beliefs, vaccine cost, and
awareness [47, 48]. By October 2014, in Africa and Asia, only 1–2% of females
aged 10–20 years received one dose of the HPV vaccine, compared to 53.4% in
Northern America, 36.4% in Europe, 41.1% in Oceania, and 22.1% in Latin
America and the Caribbean [6].
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While HPV vaccination coverage continues to improve in many jurisdictions, some
fall-off in vaccination rates has been observed [44]. Drops in coverage have been
reported in the Netherlands from 53.4 to 45.5% [49], Denmark (as low as 40%)
[50], and Ireland (50% uptake of first the dose in 2016–2017) [51]. These drops can
be explained by parents’ concerns related to vaccine safety due to misinformation
spread by certain lobby groups, often through the use of television and social media
[51]. Coordinated efforts of health authorities, civil societies, and media have been
proven efficient in reversing declining vaccination rates [51]. A special case is
represented by Japan where incorrect attributions of harm to HPV vaccine
prompted the government to withdraw support for the vaccination program in 2013
and was followed by a drastic fall in vaccine coverage [52]. This was a parallel
situation to that reported in Chile in 2016 where the Court of Talca hosted an
application for protection and decided to discontinue local HPV vaccine
administration. There are major differences in HPV coverage both at the
development level and including considerable differences in the performance of
each country’s unique program [6]. Substantial opportunities exist to increase HPV
vaccine uptake, not only in low- and middle-income countries, which have the
highest rates of cervical cancer, but also in some resource-rich settings.
3. The Psychosocial Aspects of HPV Vaccination
From its early beginnings [53, 54, 55] and through the years [1, 56, 57], from Japan
[52] to Canada [58], the HPV vaccine has stirred up controversy, even if largely
undeserved [59]. Early on, challenges arose as the HPV vaccine was associated
with sexual activity and there were unfounded claims that HPV vaccination would
lead to earlier and/or increased sexual activity in females, which caused high levels
of parental concern [60, 61, 62, 63], a claim that has now been systematically
refuted and disproven [64, 65, 66]. This controversy appears to have been unique to
the HPV vaccine, over and above the classical difficulties that come with the
introduction of any vaccine [67], even those—such as the hepatitis B vaccine—that
protect against a sexually transmitted infection. It has been said that “the HPV
vaccine has been among the most scrutinized and controversial vaccines since its
first licensure in 2006” [59].
Over the past 5 years, there has been a proliferation of studies within the behavioral
sciences trying to identify and better understand what influences HPV vaccination
intentions and vaccination uptake. As a testament to the exponential growth of
literature in this area, there are now at least 20 systematic reviews examining the
acceptability and uptake of HPV vaccination in relation to knowledge, attitudes,
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beliefs, and behaviors in a vast array of diverse populations [64, 65, 68, 69, 70, 71,
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85]. This list does not include six
published systematic reviews [86, 87, 88, 89, 90, 91] focused specifically on
interventions aimed to increase (HPV) vaccination coverage, with the most recent
examining intervention studies on HPV vaccination completion [91]. While the
search strategy, population of interest and data synthesis methods differ across the
systematic reviews, by and large there are some common themes and ideas
conveyed about how we understand HPV vaccination decision-making.
4. HPV Vaccine: Beyond Cervical Cancer
There have also been several new developments in the understanding of the
spectrum of HPV-related diseases, including the established link between HPV and
anal and oropharyngeal cancers, and the incidence of HPV+ oropharyngeal cancers
is on the rise [92]. In fact, in the USA, HPV has overtaken tobacco use as the main
cause of oropharyngeal cancer [93]
Squamous cell carcinoma (SCC) is the most frequent malignant tumor of the head
and neck, and more than 70% of oropharyngeal SCCs are HPV-associated [94].
There is preliminary evidence showing that the HPV vaccine prevents
oropharyngeal cancer [95, 96, 97], including recent findings showing an 88%
reduction of oral HPV16/18/6/11 infections in vaccinated versus unvaccinated men
and women in the USA after adjusting for age, sex, and race [98]. The authors also
estimated the population-level effect of HPV vaccination on the burden of oral
HPV16/18/6/11 infections was 17.0% reduction overall, 25.0% in women and 6.9%
in men [98]. Moreover, one population with an increased burden of HPV infection
may be carried by men who have sex with men (MSM), who have been estimated to
have an HPV-related anal cancer incidence rate that is 44 times higher than the
general population, as well as HIV-positive MSM who have an incidence rate 60
times higher than that in the population [99, 100]. Taken together, these advances
have shifted our understanding of HPV as the “cervical cancer vaccine” to an
increasing recognition that HPV does not discriminate and causes multiple diseases
among both genders [3].
5. Risk Compensation
An early HPV vaccine-related concern, promoted by the media, involved fear that
vaccinated adolescents would engage in risky and/or earlier onset of sexual
behavior following HPV vaccination [101], an issue defined as risk compensation
and/or sexual disinhibition. Since our 2013 paper [1], two systematic reviews on
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this issue were published in 2016, and both reviews concluded that there was no
evidence that getting vaccinated against HPV resulted in increased risky sexual
behavior measured by both self-report and by biological markers such as STI
diagnoses and pregnancies [64, 65]. Several studies published subsequent to the
systematic reviews continue to refute the notion that HPV vaccination may lead to
decreases in sex-related risk perceptions and increases in sexual risk behaviors
[102, 103, 104]. A recent study conducted with over 500 Canadian undergraduates
not only provided little evidence of risk compensation, it demonstrated that a
substantial proportion of HPV unvaccinated Canadian youth are already at elevated
risk of HPV-related morbidity and mortality at an early stage of their sexual careers
due to their HPV transmission risk sexual behaviors and lack of vaccine protection
[66].
Furthermore, a recent difference-in-difference study that examined the concept of
risk compensation at the policy level found that US state HPV legislation was not
associated with any increased or significant changes in riskier US adolescent sexual
behaviors [105]. In fact, the authors found the reverse: sexual intercourse decreased
by 0.90 percentage points (P = 0.21) and recent condom use increased by 0.96
percentage points (P = 0.32) among adolescents in states that had enacted HPV
vaccine legislation compared with states that had not [105], highlighting that HPV
legislation could be protective to encourage positive safe-sex behaviors.
Interestingly, while there were some earlier studies reporting that “sexual
promiscuity” post-vaccination was a concern for some parents [63], this worry
appears to be relatively uncommon [106, 107, 108, 109]. In a related vein, a recent
US study of NIS-Teen data examined reasons for parental non-initiation of HPV
vaccination, comparing 2010–2014 results [110]. The authors found that parental
concern that a child was not sexually active was a relatively commonly endorsed
reason for non-initiation in 2010 (18%), but this had significantly declined in 2014
to 9%. Similarly, results from a national study of over 3000 parents of 9- to 16-
year-old boys across Canada [111] found that only 13% of Canadian parents
somewhat or strongly agreed with this statement: “I feel that the HPV vaccine
would encourage my son to have sex at an earlier age.” Similarly, nearly 75%
“somewhat” to “strongly” disagreed that vaccinating their son for HPV would send
a message that he would not have to use safe sex practices, with only 11.1% of
parents saying that they somewhat to strongly agreed that it would (unpublished
data). Correspondingly, in a national study of 3779 parents of 9- to 16-year-old
boys and girls across Canada [112], fewer than 7% of parents “somewhat” to
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“strongly” agreed that if their child received the HPV vaccine she/he may be more
likely to have sex in the future.
Taken together, these results suggest that parental concerns about disinhibition may
have been exaggerated by media coverage and at this time are likely not a concern
for many parents. With a decline in the appearance of these stories in the media
along with more balanced reporting (i.e., presenting the scientific evidence that
adolescents do not engage in riskier sexual behavior after HPV vaccination), it is
likely concerns around this issue will continue to decline. Moreover, HCPs can use
the robust evidence against sexual disinhibition/risk compensation to alleviate any
lingering parental concerns.
6. Safety and Communication About Safety Data
In our earlier paper [1], we highlighted numerous studies attesting to HPV vaccine
safety. Five years later, the safety profiles of the three HPV vaccines have been
reviewed extensively, and the research continues to show they are safe, well
tolerated, and have adverse effects similar to those experienced with other vaccines
[12, 13, 113, 114, 115, 116]. The most common adverse effects of the vaccines are
soreness (pain), swelling, itching, and redness at the injection site, as well as
syncope (fainting) [116]. The safety profiles of the three HPV vaccines are similar
and continuously being followed in Canada, the USA, and around the world, e.g.,
via the CDC’s Vaccine Adverse Event Reporting System [117] and the Canadian
Adverse Events Following Immunization Surveillance System (CAEFISS) [118].
While media reports have extensively presented stories regarding adverse effects of
the vaccine (real or fatuous; see, e.g., Toronto Star, now rescinded [119]), little has
been written in the media regarding the profound effects of not being vaccinated,
i.e., increased risk of genital warts and HPV-related cancers later in life.
Despite the plethora of scientific evidence, ominous reports of HPV vaccine harm
have continued to circulate, having a significant impact on HPV vaccine uptake
rates in many countries (e.g., Austria, Columbia, Denmark, Ireland, and Japan). In
the Republic of Ireland, a group called Reactions and Effects of Gardasil Resulting
in Extreme Trauma (REGRET) demanded an injunction from the High Court for a
withdrawal of the vaccine across the country. Vaccination rates dropped to just 51%
as a result [120]. In Columbia, a class action lawsuit of over 700 women has been
filed alleging that they have been damaged by the HPV vaccine [16, 17, 52, 121]. In
Japan, the Health Ministry withdrew its recommendation for 4vHPV, though the
vaccine is still available. Tireless efforts by many researchers, clinicians, and
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advocacy groups worldwide (e.g., Drs. Riko Muranaka and Sharon Hanley from
Japan, Dr. Juliette Guichon from Canada) have vigorously worked to counter the
scientifically unjustified assertions of vaccine adverse effects and harms [122, 123].
Fortunately, for some countries, the decline was temporary (e.g., Austria and
Brazil) [124]; for others there has been some slow recovery (e.g., Ireland [18]).
Japan’s program has suffered greatly, with HPV vaccination rates plummeting from
70% (in 2013) to less than 1% currently, meaning that substantial numbers of
Japanese youth will remain susceptible to HPV-related pre-cancers and cancers for
years to come [16, 17, 121].
7. Healthcare Provider’s Influence on HPV Vaccine
Uptake
The centrality and importance of the HCP was highlighted in our 2013 paper [1].
We also explored the variability in provider recommendation due to time
constraints, patient’s age, availability of insurance or other coverage, provider’s
views, and level of comfort, e.g., their own safety and/or efficacy concerns, and
hesitancy in discussing sexuality. We had some earlier indications about what might
help to increase the impact of a provider’s recommendation, e.g., message framing.
To date, the role of the HCP remains largely unchanged, with continued evidence to
support that one of the strongest predictors of both HPV vaccine initiation and
completion is recommendation from an HCP [69, 80, 85, 125, 126, 127, 128]. The
lack of an HCP recommendation is similarly an important barrier to HPV
vaccination. What we can now add to this is that the quality/type of
recommendation matters [129, 130, 131, 132]. In two studies examining audio
recordings of HCP conversations with parents, HCPs made relatively weak, non-
presumptive recommendations for HPV vaccination [130, 131]. The rate of HPV
vaccination completion is higher when the HCP makes a consistent, same-day
recommendation, and emphasizes cancer prevention [133, 134] in contrast with an
inconsistent or without an urgency recommendation [129]. Similarly, research
shows that when HCPs are trained to make a presumptive recommendation (i.e., a
clear brief statement that assumes parents are ready to vaccinate, also termed
“announcements”), modest but significant increases in HPV vaccine initiation rates
can be achieved [132]. Another effective strategy is to bundle the HPV vaccine
with other vaccinations [130].
HCPs themselves report lack of knowledge, discomfort, and/or can be misinformed
by information they received from the internet related to HPV vaccination.
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Providing additional training to HCPs related to HPV vaccination could help
mitigate the different barriers that HCPs report. First and foremost, HCPs need to
be made aware of the wide availability of resources such as clinician fact sheets,
toolkits, videos, and e-learning modules that can help them both general
information and with their recommendation (e.g., from agencies like the CDC, the
WHO, Catalan Institute of Oncology; see Session 4: Materials available for in
service training of HCP: https://www.uantwerpen.be/en/projects/hpv-prevention-
control-board/meetings-/hpv-romania/). Second, creating an infrastructure that
continues to help support HCPs to have these discussions and assist them in making
impactful, strong recommendations [130, 132, 135] will be key to improving HPV
vaccine uptake. Thirdly, once an HCP feels well equipped, opportunities exist to
have HCPs adapt existing resources and materials to their own cultures/locations as
well as effectively communicate and advocate with the media/press and amplify key
messages through their own and/or institution’s social media platforms. The use of
social media to promote pro-HPV vaccination messages can be one strategy to
refute the misleading yet impactful anti-vaccination messages that are widely
available on the web and social media.
One avenue worthy of exploration is who is best suited to provide information on
the vaccine recommendation, and who should administer the vaccine. A recent
examination of pediatricians’ views as part of a randomized controlled trial
involving clinical decision support reminders highlighted that half of the physicians
pointed to the key role of their nurse(s) in the vaccination setting. Ideally, nurses
would be both allowed and encouraged to administer vaccinations without approval
from a physician (e.g., via standing orders). This approach has been shown to be
more effective in increasing vaccine rates as compared to clinical decision
reminders geared toward physicians [136]. Other potential providers may include
pharmacists [137], who depending on the healthcare system, could administer
directly at the pharmacy.
8. The Age of Vaccination
Across the globe, the age of HPV vaccination has varied widely, with some children
being vaccinated as early as 9 years old, and others in high/middle school (12 years
and above), and/or up to 18, 21, 24, or 28 years old. Many programs and providers
are recommending vaccine initiation at ages 9 or 10 years, as it is optimal that the
two-dose series be completed by age 11 years. The child’s age has been shown to
influence parents’ HPV vaccine acceptance, with mixed findings on whether
parents are more likely to vaccinate if their child is older or younger. What we do
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know is that there are qualitative differences between childhood and mid to late
adolescence. These periods are marked by changes in social, physical, and
neurocognitive statuses. As children pass through puberty (~ 10–14 years old),
there are changing notions of privacy, increased behavioral autonomy, and
increased parent-child conflict [17]. This raises the issue of what is the optimal age
of HPV vaccination.
Medico-legal issues including the capacity of adolescents to consent to medical
treatment on their own behalf, parental authority, and confidentiality become
particularly pertinent with respect to HPV vaccination involvement. In most
countries’ legal systems, the legal age of consent tends to coincide with the age of
majority, typically 18 years of age [25]. In a growing number of countries, the age
of consent for medical treatments is set below the age of majority [25]. Some
countries have even fixed the age of consent specifically to allow HPV vaccination
at 12 years of age [25].
Since laws regarding HPV vaccination for young people under 18 years vary widely
from country to country and even amongst states/provinces/regions, much is often
left to the judgment of the healthcare professional as to the maturity of the young
person and their capacity to consent, particularly in regions with no school-based
vaccination programs [25]. In school-based immunization programs, e.g., Austria,
Australia, and Canada, there are different issues at play as the parent may sign the
consent form, but the student may refuse immunization and it will not be given or
vice versa, i.e., the parent refuses to sign, but the student is judged capable of
giving informed consent, is requesting the vaccine, and will be given their
immunization. This is further complicated by paradoxes in vaccine policy and
adolescent consent laws. While some have stated that parental consent for
vaccination may present a significant barrier to improving adolescent vaccine
uptake [27], the authors are highlighting that the ideal age of HPV vaccination has
yet to be established. From a biomedical perspective, vaccination before age
16 years will capitalize on optimal immunogenicity and minimal likelihood of prior
HPV infection.
An important point to consider is that vaccinating against HPV in pre-puberty
(typically 9–12 years of age) as opposed to during or post puberty is recommended
because it provides immunity prior to sexual activity debut (possibly being exposed
to HPV transmission) and could be more easily accepted by the child-parent dyad.
During puberty, there is an increased likelihood that child-parent conflicts and
parents’ difficulties in communicating [126] about sexuality with their child could
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negatively influence HPV vaccine acceptability. Moreover, in publically funded
programs, if vaccination does not occur during the recommended time frame, there
are often no publicly funded catch-up programs for young adults (e.g., early
twenties and beyond), and the issue of cost often surfaces. For example, for the
40% of unvaccinated Ontarians who are not vaccinated by age 18 years, many do
not see HPV vaccine as a priority and cannot afford to pay for the vaccine [66].
These are all important considerations for vaccination programs and policy. Future
research may also consider the effectiveness of vaccinating children prior to 9 years
of age.
9. Conclusions
Public scrutiny of the HPV vaccine is indispensable. This prompts researchers,
scientists, politicians, and stakeholders to not only continuously evaluate the
effectiveness, safety, and overall utility of the HPV vaccine, but also to work hard
to provide sound, empirical evidence that the benefits outweigh any potential
harms. Unfortunately, much of the work surrounding HPV vaccination that is
widely available to the public (e.g., media) has been clouded with myths and
misinformation, speculation, and a priori doubts/worries that are presented as
empirical science. These controversies and challenges have arisen from
misinformation and disregard of scientific evidence, stemming from distrust of
institutions, the pharmaceutical industry, and biomedical technologies [138, 139,
140]. One such controversy was that of risk compensation, which is no longer a
valid argument to prevent HPV legislation [105], and appears to be less and less of
a concern among most parents. Nonetheless, continued concerns about the safety of
the HPV vaccine linger. With over a decade of extensive high-quality science, and
the backing from the medical and research communities, it is very clear that the
HPV vaccine is a safe and effective vaccine that is critical for cancer prevention.
In the next 2 years (by 2020), the highest number of HPV-related cancer deaths in
many high-income countries will be oropharyngeal. This draws more and more
attention to HPV-associated cancers that affect both men and women. Over the next
few years, we can also anticipate continued advances with respect to the vaccines
themselves, age of vaccination, and dosing schedules. For example, similar to the
shift from a three-dose schedule to a two-dose schedule, research is currently
underway considering the pairing of the 9vHPV and the 2vHPV as a way to elicit a
strong immunity response at an affordable price. Another example is a current
clinical trial looking at whether administering one dose of either 2vHPV or 9vHPV
vaccines are as effective as giving two doses of these vaccines to women aged 12–
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16 years [141].These are additional contributing factors that could increase HPV
vaccine uptake rates globally, especially in middle- and low-income countries,
which account for 86% of cervical cancer cases worldwide [6].
With over a decade of research behind the HPV vaccine, the tide has shifted and the
successes appear to be outweighing the challenges. While this is promising, many
individual policies (i.e., males, young adults) for those who could benefit from
HPV vaccination are still not being implemented and the individuals are still not
receiving the vaccine and/or are not being considered in HPV vaccination programs
and in the implementation of country policies, particularly in low-income and
lower-middle-income countries. The wide variability of uptake rates across the
globe can be explained by differences in policy and socioeconomic disparities,
though in many countries the amount and content of social media information (i.e.,
Twitter; Facebook) has accounted for a greater part of the difference than
socioeconomic status. This suggests that the information that we acquire via the
media, which in turn shapes our attitudes and opinions, may “give the biggest bang
for the buck” in terms of influencing HPV vaccine rates. Using push technology to
provide up-to-date information related to HPV vaccination to HCPs could represent
an important initiative as one of the major barriers towards HPV vaccination is
providers’ lack of time [142]. Informing and training pediatricians, general
practitioners, and obstetricians/gynecologists is a first step to improve HPV
vaccination dose completion in females and males [143]. Importantly, the ideal goal
would be to ensure that all HCPs who are providing the HPV vaccination are well
trained and confident when providing information to patients. Working within the
various media forms to convey the science to the lay public, as well as working to
establish strategies with HCPs to provide strong recommendations in the most ideal
settings, i.e., school-based programs, standing orders, can ultimately increase HPV
vaccination rates and reduce worldwide morbidity and mortality in a meaningful
fashion [143].
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